SkinDermic has developed novel, safer and highly effective first-in-class drug candidates, internally discovered, for the treatment of acne, Kaposi’s Sarcoma and other HHV8 associated diseases.

SkinDermic® as completed Phase-1/2 (proof of concept) clinical trials of its First-in-Class treatments for acne and Kaposi’s sarcoma.

In parallel, SkinDermic® also develops, using its own advanced research programs, biotechnology-derived first-in-class ingredients for use as cosmetics.

The Company owns 5 first-in-class, internally discovered, molecules candidates for clinical development including:

  • SDA-001, SDA-002 and SDA-003, anti-inflammatory molecules developed for topical use for human acne,
  • SDK-001 and SDK-002, pro-apoptotic molecules for human Kaposi’s sarcoma that act selectively in HHV-8 infected cells.
  • SDL-006, anti-melanogenic ingredient for lightening


SkinDermic Pipeline – 12/2020